Dr. Jack Cush on Pseudogout
Dr. Philip Robinson at EULAR18 on Gout Abstracts
The ACP has not helped with their ridiculous guidelines for management of Gout.
— AT (@RheummanArnaldo) June 16, 2018
#eular18 @RheumNow ABST sat0358 Pts w/gout &T2DM have longer duration of gout (63 vs 41 mo), more likely to have tophi (37% vs 20%), joint damage (24% vs 13%) & severe gout (27% vs 13%) vs pts w/o T2DM (p<0.01). ER visits 17% vs 9% & hospitalizations 5% vs 2% p<0.001 pic.twitter.com/gN8DnAWAcO
— Olga Petryna (@DrPetryna) June 16, 2018
#eular18 @RheumNow ABST sat0356 Pegloticase leads to fast resolution of all visualised tophi in ~6.98, 7.14 and 12.02 mos for pts w/ low, medium and high BL tophus burden (p<0.0001). The rate of response inversely correlates w/total tophus burden at the beginning of Rx pic.twitter.com/fKhYwmK1OF
— Olga Petryna (@DrPetryna) June 16, 2018
#eular18 @RheumNow ABST sat0357 only 51.7% of pts compliant with ULT ( allopurinol&uloric predominantly) after 1 year. The median time to discontinuation 248 days. Older, male & those who get their Rx from a rheumatologist are more likely to stay compliant pic.twitter.com/s1ZYzoq0p2
— Olga Petryna (@DrPetryna) June 16, 2018
Abstract Sat 0356 showed pegloticase results in rapid resolution of tophus in bio chemical responders but is not influenced by age gender, race, BMI, tophus location. #EULAR pic.twitter.com/rUWEHEA2fZ
— Dr. John Cush (@RheumNow) June 16, 2018
Asaiphanit. Another study (from Thailand) demonstrating poor compliance (56.6%), failure to meet SUA target (70.8%) in gout. Once again where treatment initiated by rheumatologist better adherence to treatment. #EULAR2018 @RheumNow ABST SAT0371
— Ronan Kavanagh (@RonanTKavanagh) June 16, 2018
Vazquez-Mellado. Mexican patients with severe gout tend to be younger age at onset, lower educational level and socioeconomic status. Despite receiving higher allopurinol (>600mg) only 50% achieved target uric acid. #EULAR2018 @RheumNow ABST SAT0363
— Ronan Kavanagh (@RonanTKavanagh) June 16, 2018
Jansenn. Compliance in patients with gout on Uric acid lowering therapy at 1 yr was 51.7%. Better compliance if initiated by rheumatologist 🙂 #Eular2018 @RheumNow ABST SAT0357 pic.twitter.com/4JDvGWfp4Z
— Ronan Kavanagh (@RonanTKavanagh) June 16, 2018
A sore toe can kill you! Danish population study excluded past cancers and found pts with goit had mor cancer. Lymphoma could cause gout prior to detection but many were lifestyle cancers from alcohol & metabolic syndrome FRI0221 #EULAR2018 @RheumNow pic.twitter.com/tyYvXlgnUN
— Janet (@Janetbirdope) June 15, 2018
Dr. Janet Pope at EULAR18: Gout Cancer Connection?
Dr. Peter Lipsky at EULAR 2018: Pegloticase “Triple” study
Ready for another great day, lots of #gout today 👏 #EULAR2018 @RheumNow pic.twitter.com/h9VB8qJveN
— Philip Robinson (@philipcrobinson) June 14, 2018
And we’re off with the crystal abstract session with a CPPD abstract #EULAR2018 @RheumNow pic.twitter.com/j2LHCFHKWb
— Philip Robinson (@philipcrobinson) June 14, 2018
Spanish data from Perez-Ruiz on 650 CPPD patients has shown HFE genotypes C282Y and H63D are associated with worse CPPD #EULAR2018 @RheumNow ABT OP0183 pic.twitter.com/6l3prucUcW
— Philip Robinson (@philipcrobinson) June 14, 2018
Lovely CPPD study which confirmed the diagnosis with synovial fluid on all patients. First study to do this @RheumNow #EULAR2018 pic.twitter.com/Cdh15jUfwu
— Philip Robinson (@philipcrobinson) June 14, 2018
Analysis of pegloticase trial data has shown that flares increased the most in monthly admin pts who responded. Likely due to changes in serum urate. So the take home seems to be to use
pegloticase as recommended at a 2 week dosing interval #EULAR2018 @RheumNow ABT OP0184 pic.twitter.com/1HyJpOGgx8— Philip Robinson (@philipcrobinson) June 14, 2018
This is the slide that shows why q2 week treated patients flare less. Less variation in uric acid @RheumNow #EULAR2018 ANT OP0184 pic.twitter.com/tSa6ZupgfE
— Philip Robinson (@philipcrobinson) June 14, 2018
The mobilisation flare theory that helps explain why variation in serum uric acid contributes to flare in gout #EULAR2018 @RheumNow pic.twitter.com/TSPfraYcai
— Philip Robinson (@philipcrobinson) June 14, 2018
There has been a huge increase in emergency department admission for gout in the US, up to 28% increase over the period 2006 to 2014. Biggest increase in those 45-64 years old #EULAR2018 @RheumNow ABT OP0185 pic.twitter.com/o1YODtly8k
— Philip Robinson (@philipcrobinson) June 14, 2018
Brazilian study where they did CT scans on patients with gout to determine if they had kidney stones. They found 30% had stones whereas only 16% reported stones in questioning. Stone presence associated with high urate (>8.5mg/dL) and acid urine #EULAR2018 @RheumNow ABT OP0186 pic.twitter.com/InyeDb7h1f
— Philip Robinson (@philipcrobinson) June 14, 2018
Increasing incidence and prevalence in gout in Belarus over 2011-2015 #EULAR2018 @RheumNow ABT FRI0253 pic.twitter.com/gK8V9Vf649
— Philip Robinson (@philipcrobinson) June 15, 2018
More people in the US are reaching target serum urate in #gout @RheumNow #EULAR2018 ABT FRI0251 pic.twitter.com/DVrYmitXG6
— Philip Robinson (@philipcrobinson) June 15, 2018
Really interesting study looking at outcomes in #gout by their care location by Roddy. GP F/U not as good as specialty care #EULAR2018 @RheumNow ABT FRI0249 pic.twitter.com/phYfDtVYXI
— Philip Robinson (@philipcrobinson) June 15, 2018
Pegloticase treatment reduced blood pressure in the gout clinical trials. Looks like about 8-10mmHg on average from the graphs #EULAR2018 @RheumNow ABT FRI0237 pic.twitter.com/QZnwiMtUE8
— Philip Robinson (@philipcrobinson) June 15, 2018
Nice study on US NHANEs data showing raised lead levels correlate with gout #EULAR2018 @RheumNow ABT FRI0222 pic.twitter.com/9CbhqPne8m
— Philip Robinson (@philipcrobinson) June 15, 2018
Choi. Decrease in Mean Arterial Blood Pressure SPB and DBP with use of pegloticase in chronic gout. Tends to correlate with response. #eular2018 @RheumNow ABST FRI0237 pic.twitter.com/7s7M6QD3mf
— Ronan Kavanagh (@RonanTKavanagh) June 15, 2018
Dr. Philip Robinson at EULAR2018 on Gout Studies
Dr. Jack Cush at EULAR 2018 – DECT Scanning in Gout
Dr. Olga Petryna – Canakinumab in CVD Pts Prevents Acute Gout Attacks
Medicare claims data finds among 1.7 million people, 14,279 developed MI: 13,029 MIs in pts without #gout & 1250 MIs in gout pts, w/ crude incident rates of 1.3 vs 4.1 per 1000 pt-yrs. Gout significantly associated with higher rate of incident MI, HR 2.08 https://t.co/2zL12THFn1
— Dr. John Cush (@RheumNow) June 13, 2018
Dr Solomons plenary session on CANTOS substudy in @risk CVD pts shows Canakinumab lowered the risk of acute gout attacks by 50-60%, lowered hsCRP but not SUA levels. #EULAR2018 @RheumNow OP0014 pic.twitter.com/7eWwHKDwrn
— Dr. John Cush (@RheumNow) June 13, 2018
For all you #gout fanatics there is a great session on Saturday on the links between gout and kidney function. Midday on Saturday. Be there or be square. #EULAR2018 @RheumNow
— Philip Robinson (@philipcrobinson) June 13, 2018